Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study

Table 3 Summary of GSD type Ib patients’ follow-up after empagliflozin treatment

Patient	Age	Dosage	Duration of treatment (month)	Neutrophils count (10⁹/L)		Hematocrit (%)		Hemoglobin (g/L)		Platelet count (10⁹/L)		Urine glucose
Patient	Age	Dosage	Duration of treatment (month)	Before^c	Latest	Before	Latest	Before	Latest	Before	Latest	Urine glucose
2	12y6m	5 mg q.d.	12	1.65	1.29	30.5	43.3	97	129	346	431	Increased
5	13y	5 mg q.d.	12	1.15	1.25	37.6	44.4	114	138	408	465	Normal
7	10y1m	5 mg q.d.	10	0.73	0.90	23.9	31.5	71	91	627	588	ND
10	9y6m	5 mg q.d.	11	1.14	2.05	28.7	30.5	86	93	805	674	Increased
15	8y2m	5 mg q.d.	10	0.69	2.01	33.1	35.8	115	121	363	399	ND
23	4y6m	3 mg q.d.	10	4.61	1.14	31.5	33.3	95	102	607	529	Increased
24	7y5m	5 mg q.d.	10	0.70	0.90	33.0	35.1	104	109	441	405	ND
26	4y7m	5 mg q.d.	18	1.01	2.40	30.6	40.4	91	131	925	568	ND
28	7y11m	5 mg q.d.	10	1.91	1.39	33.1	33.3	110	115	342	520	Normal
29	3y11m	3 mg q.d.	28	0.20	0.40	30.8	34.0	99	112	427	359	Increased
31	5y	5 mg q.d.	16	2.51	1.89	37.0	37.1	120	121	413	484	ND
33	4y6m	3 mg q.d.	6	0.46	1.66	30.3	34.0	98	107	535	548	ND
34	3y8m	2.5 mg q.d.	8	2.84	2.48	33.6	33.0	107	111	496	445	Increased
35	2y8m	2.5 mg q.d.	14	0.44	0.86	33.3	36.7	108	121	738	748	ND
Median			10.5	1.08	1.34	32.3	34.6	102	114	467	502
Percentile (25%,75%)			10, 13.5	0.69,1.85	0.96,1.98	30.5,33.3	33.3,37	97,110	108,121	409,622	435,563
Reference				2.00-7.20		36.0–46.0		118–156		178–410

ISSN: 1750-1172